ES2023552A6 - Nimesulid inclusion cpds. with cyclodextrin - more water-soluble with improved bio-availability than nimesulid alone - Google Patents
Nimesulid inclusion cpds. with cyclodextrin - more water-soluble with improved bio-availability than nimesulid aloneInfo
- Publication number
- ES2023552A6 ES2023552A6 ES9001566A ES9001566A ES2023552A6 ES 2023552 A6 ES2023552 A6 ES 2023552A6 ES 9001566 A ES9001566 A ES 9001566A ES 9001566 A ES9001566 A ES 9001566A ES 2023552 A6 ES2023552 A6 ES 2023552A6
- Authority
- ES
- Spain
- Prior art keywords
- nimesulid
- cyclodextrin
- cpds
- soluble
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 3
- 230000001741 anti-phlogistic effect Effects 0.000 abstract 2
- 239000001116 FEMA 4028 Substances 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 abstract 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 abstract 1
- 229960004853 betadex Drugs 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Nanotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Nimesulid inclusin cpds. (I) with betacyclodextrin alpha,beta and gamma or in their aq. are new and/or have molar ratio nimesulid:cyclodextrin 1:0.5 - 1:15. Pref. the cyclodextrin is of beta-type and. USE/ADVANTAGE - (I) shows improved bioavailability and increase the max. plasma concn. of the nimesulid, which is an antiphlogistic used in the treatment of articular and extraarticular inflammations and is very sparingly soluble and of low bioavailability. (I) have analgesic and antiphlogistic properties and are well soluble in water thus ensuring that the nimesulid is more rapidly resorbed. Suitable unit doses contain 20-150 mg (I). (9pp Dwg.No.0/3)
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES9001566A ES2023552A6 (en) | 1990-05-22 | 1990-05-22 | Nimesulid inclusion cpds. with cyclodextrin - more water-soluble with improved bio-availability than nimesulid alone |
ITMI911396A IT1255982B (en) | 1990-05-22 | 1991-05-21 | INCLUSION COMPOUNDS OF NIMESULIDE WITH CYCLODESTRINE AND PROCEDURE FOR THE PREPARATION OF SUCH COMPOUNDS |
DE4116659A DE4116659C2 (en) | 1990-05-22 | 1991-05-22 | Cyclodextrin nimesulide inclusion compounds, processes for making them and medicaments containing them |
FR9106165A FR2662360B1 (en) | 1990-05-22 | 1991-05-22 | COMPOUNDS FOR INCLUDING NIMESULIDE WITH CYCLODEXTRIN, METHODS FOR THE PREPARATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS WITH ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY CONTAINING THE SAME. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES9001566A ES2023552A6 (en) | 1990-05-22 | 1990-05-22 | Nimesulid inclusion cpds. with cyclodextrin - more water-soluble with improved bio-availability than nimesulid alone |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2023552A6 true ES2023552A6 (en) | 1992-01-16 |
Family
ID=8267635
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES9001566A Expired - Fee Related ES2023552A6 (en) | 1990-05-22 | 1990-05-22 | Nimesulid inclusion cpds. with cyclodextrin - more water-soluble with improved bio-availability than nimesulid alone |
Country Status (4)
Country | Link |
---|---|
DE (1) | DE4116659C2 (en) |
ES (1) | ES2023552A6 (en) |
FR (1) | FR2662360B1 (en) |
IT (1) | IT1255982B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1255462B (en) * | 1992-07-28 | 1995-11-02 | Grazia Maffione | METHOD OF PREPARATION OF NIMESULIDE INCLUSION COMPOUNDS WITH CYCLODESTRINE |
IT1291278B1 (en) * | 1996-07-05 | 1999-01-07 | Errekappa Euroterapici S P A | NIMESULIDE-BASED PHARMACEUTICAL PREPARATION FOR TOPICAL USE |
IN186315B (en) * | 1996-12-12 | 2001-08-04 | Panacea Biotec Ltd | |
IT1291895B1 (en) | 1997-04-24 | 1999-01-21 | Errekappa Euroterapici S P A | FLUID PHARMACEUTICAL PREPARATION BASED ON NIMESULIDE FOR ORAL AND RHINOPHARYNGAL USE |
BRPI0710916A2 (en) * | 2006-04-24 | 2011-08-23 | Panacea Biotec Ltd | low dose nimesulide-containing pharmaceutical compositions; preparation and use |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR206496A1 (en) * | 1972-07-03 | 1976-07-30 | Riker Laboratories Inc | PROCEDURE FOR THE PREPARATION OF 2-PHENOXY-4-NITRO-ALKYL OR HALOALKYLSULPHONANILIDES |
GB8613688D0 (en) * | 1986-06-05 | 1986-07-09 | Euro Celtique Sa | Pharmaceutical composition |
-
1990
- 1990-05-22 ES ES9001566A patent/ES2023552A6/en not_active Expired - Fee Related
-
1991
- 1991-05-21 IT ITMI911396A patent/IT1255982B/en active IP Right Grant
- 1991-05-22 FR FR9106165A patent/FR2662360B1/en not_active Expired - Fee Related
- 1991-05-22 DE DE4116659A patent/DE4116659C2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ITMI911396A1 (en) | 1992-11-21 |
IT1255982B (en) | 1995-11-17 |
FR2662360A1 (en) | 1991-11-29 |
DE4116659A1 (en) | 1991-11-28 |
FR2662360B1 (en) | 1993-07-30 |
ITMI911396A0 (en) | 1991-05-21 |
DE4116659C2 (en) | 2000-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ501066A (en) | Pharmaceutical formulations containing voriconazole and sulphobutylether beta-cyclodextrin | |
PT620828E (en) | CYCLODEXTRIN DERIVATIVES SHOWING BETTER SOLUBILITY IN WATER AND THEIR USE | |
BG104680A (en) | Celecoxib compositions | |
LU91223I2 (en) | Ivabradine and its pharmaceutically acceptable derivatives (procoralan) | |
DE69910230D1 (en) | MEDICINAL PRODUCTS CONTAINING PACLITAXEL | |
CY1110988T1 (en) | HIGHLY DETERMINED SOLID PREPARATION | |
TWI265808B (en) | Valdecoxib compositions | |
RO116342B1 (en) | Oral liquid pharmaceutical composition | |
MY106272A (en) | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants. | |
NO962088D0 (en) | Preparation for in vivo production of therapeutic products | |
DK0793495T3 (en) | Freeze-dried ondansetron preparations | |
WO2000021510A3 (en) | Formulations of fexofenadine | |
IL146125A0 (en) | Novel quinones as disease therapies | |
IT1269578B (en) | MULTI-COMPONENT INCLUSION COMPLEXES WITH HIGH SOLUBILITY CONSISTING OF AN ACID TYPE DRUG, A CYCLODESTRINE AND A BASE. | |
ITMI911155A1 (en) | HIGH VISCOSITY AND LOW PEROXIDE OXYGEN PERFLUOROPOLYETERS, AND PROCEDURE FOR THEIR PREPARATION | |
ES2023552A6 (en) | Nimesulid inclusion cpds. with cyclodextrin - more water-soluble with improved bio-availability than nimesulid alone | |
DE69521275T2 (en) | Pharmaceutical preparations containing cefaclor | |
DE60006788D1 (en) | IOD PRODUCTION COMPOSITION | |
MXPA02011533A (en) | NOVEL FORMULATIONS OF agr; 2, 4 DISULFOPHENYL N TERT BUTYLNITRONE. | |
GEP20043313B (en) | Use of Pharmaceutical Composition for Treatment of Endometriosis or Infertility, or Improving Fertility | |
GEP20074097B (en) | Use of specific dose of fondaparinux sodium for the treatment of acs | |
NO960347D0 (en) | Use of benzydamide in the treatment of pathological conditions caused by TNF | |
IT1252160B (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING THE PEPTIDOGLICAN OF LACTOBACILLUS CASEI | |
ITBO960018A0 (en) | USE OF LOW MOLECULAR WEIGHT DERMATANE SULFATOA AND SPECIAL MEDICINAL PRODUCTS THAT CONTAIN IT IN THE THERAPY AND PREVENTION OF PULMONARY EMBOLISM. | |
ATE145135T1 (en) | USE OF RILUZOLE TO PROTECT AGAINST RADIATION DAMAGE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC1A | Transfer granted |
Owner name: PATPHARM HOLDING, S.A. |
|
FD1A | Patent lapsed |
Effective date: 20050523 |